Abstract
Context: Shenqi FuZheng injection (SFI) has been suggested as a complementary treatment of chemotherapy in China. However, little is known about it in western countries.Objective: This study assesses the clinical effect of SFI combined with chemotherapy for breast cancer patients.Materials and methods: Both English and Chinese databases were searched covering the time period of 1999– 2018 for relevant studies comparing the effect of SFI plus chemotherapy treatment with chemotherapy alone in patients with breast cancer. Target outcomes concerning treatment effect, performance status, immune system and toxic effects were extracted and combined using Stata version 15.0 software. Quality assessment was performed using the Jadad scale.Results: Forty-nine trials were included based on certain selection criteria. Only seven studies were rated as high-quality publications. Results of meta-analysis showed that SFI intervention can significantly improve objective tumour response, performance status, NK, CD3+, CD4+ and CD4+/CD8+ ratio and reduce occurrence of leucopenia, thrombocytopenia, haemoglobin reduction, liver dysfunction, gastrointestinal reaction, nausea and vomiting, bone marrow suppression and ECG changes. However, no significant difference was found between SFI and the control group regarding CD8+ levels, and renal disorders.Discussion and conclusions: SFI intervention appeared to be effective in improving clinical efficacy, immune function and reducing toxicity when combined with chemotherapy for breast cancer. However, our findings still need verification by high-quality trials.
Highlights
Breast cancer is one of the most prevalent cancers and the second leading cause of death among women
Results of meta-analysis showed that Shenqi FuZheng injection (SFI) intervention can significantly improve objective tumour response, performance status, natural killer cell (NK), CD3þ, CD4þ and CD4þ/CD8þ ratio and reduce occurrence of leucopenia, thrombocytopenia, haemoglobin reduction, liver dysfunction, gastrointestinal reaction, nausea and vomiting, bone marrow suppression and ECG changes
No significant difference was found between SFI and the control group regarding CD8þ levels, and renal disorders
Summary
Breast cancer is one of the most prevalent cancers and the second leading cause of death among women. In 2019, 268,600 new breast cancer cases were estimated in US, accounting for approximately 30% of all new cases in women. The estimated mortality rate was lower than that in 2002–2012, the increasing number of new cases each year still made breast cancer an utmost important health care issue and economic burden worldwide (Montero et al 2012; Tao et al.2015). It is urgent for effective preventive and treatment for breast cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
